MGI PHARMA (MOGN) Said Aquavan NDA Accepted for Review by FDA
More News related to MOGN
- S&P Announces Changes to U.S. Index
- MGI PHARMA (MOGN) sNDA for Aloxi Capsules Accepted for Review By the FDA
- MGI PHARMA (MOGN) Said Aquavan NDA Accepted for Review by FDA
- Unusual 11 Mid-Day Movers: MBIA, PMI Higher; Celegene Lower on Clinical Results (MBI, PMI, CELG)
- Notable Analyst Rating Changes: CC, GMST, FL Up; EMR, PALM, MOGN Down
MGI PHARMA, INC. (Nasdaq: MOGN) announced that the New Drug Application for Aquavan Injection was accepted for filing by the FDA. Aquavan is an investigational drug that is being studied as a sedative-hypnotic agent in patients undergoing diagnostic or therapeutic procedures.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
